These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37540162)

  • 1. Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study.
    Dwyer JP; Agiro A; Desai P; Cremisi H
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1057-1066. PubMed ID: 37540162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
    McEwan P; Hafner M; Jha V; Correa-Rotter R; Chernin G; De Nicola L; Villanueva R; Wheeler DC; Barone S; Nolan S; Garcia Sanchez JJ
    J Med Econ; 2023; 26(1):1407-1416. PubMed ID: 37807895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis.
    Chang RC; Huang J; Hurst J; Reck D; Khachatourian K; Shannon MH
    J Manag Care Spec Pharm; 2024 Aug; 30(8):834-842. PubMed ID: 39088339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
    Tisdale RL; Cusick MM; Aluri KZ; Handley TJ; Joyner AKC; Salomon JA; Chertow GM; Goldhaber-Fiebert JD; Owens DK
    J Gen Intern Med; 2022 Oct; 37(13):3380-3387. PubMed ID: 35137296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
    Tangri N; Rastogi A; Nekeman-Nan C; Hong LS; Ozaki A; Franzén S; Sofue T
    Adv Ther; 2024 Mar; 41(3):1151-1167. PubMed ID: 38240949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
    McEwan P; Darlington O; Miller R; McMurray JJV; Wheeler DC; Heerspink HJL; Briggs A; Bergenheim K; Garcia Sanchez JJ
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1730-1741. PubMed ID: 36323444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.
    Chang RC; Miller RL; Kwon KW; Huang JC
    Adv Ther; 2024 Aug; 41(8):3247-3263. PubMed ID: 38958842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
    Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M
    Am J Hypertens; 2024 May; 37(6):438-446. PubMed ID: 38436491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
    McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Hou FF; Rossing P; Sjöström CD; Solomon SD; Toto RD; Langkilde AM; Heerspink HJL;
    JACC Heart Fail; 2021 Nov; 9(11):807-820. PubMed ID: 34446370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
    Vareesangthip K; Deerochanawong C; Thongsuk D; Pojchaijongdee N; Permsuwan U
    Adv Ther; 2022 Mar; 39(3):1279-1292. PubMed ID: 35038121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
    Parker ED; Wittbrodt ET; McPheeters JT; Frias JP
    Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
    Norhammar A; Bodegard J; Nyström T; Thuresson M; Rikner K; Nathanson D; Eriksson JW
    Diabetes Obes Metab; 2019 Dec; 21(12):2651-2659. PubMed ID: 31379124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.